Lab study maps ovarian clear cell tumors from core to edge

Cancer cells do not occupy the same biological state from one side of a tumor to the other. At National Taiwan University College of Medicine, a team led by Professor Ruby Yun-Ju Huang has built the first spatial atlas of ovarian clear cell carcinoma (OCCC), showing differences between the tumor core and its edges.

The researchers combined GeoMx, Visium and CosMx spatial transcriptomics—methods that measure gene activity while preserving each cell’s location—with functional validation and a chick embryo chorioallantoic membrane model. They examined both primary and metastatic OCCC samples, rather than treating each tumor as a uniform mass.

The contrast was sharp. Cells in the center had higher oxidative phosphorylation (OXPHOS), the energy-producing activity of cells, and more epithelial characteristics. Cells closer to invasion, necrosis and hemorrhage showed progressively lower metabolic activity and greater epithelial-mesenchymal transition (EMT), a change in cell state linked here to the tumor’s ability to adapt across different environments.

The atlas also pointed to a molecular mechanism. Higher activity of the metabolism-related gene LCN2 was associated with stronger OXPHOS and epithelial traits. Patient samples with high LCN2 and pronounced epithelial characteristics were associated with a relatively better overall prognosis. The team’s single-cell spatial analysis and functional assays indicated that the transcription factor SOX9 regulates LCN2, forming an axis that may govern these state changes.

So what changes concretely? For researchers, the map offers new insights into disease progression and potential therapeutic strategies. The SOX9–LCN2 axis is a potential lead for more precise strategies, but the study does not establish a therapy: its findings come from tumor samples and laboratory validation, and further work is needed before clinical use.